ponazuril and Body-Weight

ponazuril has been researched along with Body-Weight* in 2 studies

Other Studies

2 other study(ies) available for ponazuril and Body-Weight

ArticleYear
Efficacy of treatment of elevated coccidial oocyst counts in goats using amprolium versus ponazuril.
    Veterinary parasitology, 2016, Mar-15, Volume: 218

    Coccidiosis is an important disease of young goats leading to weight loss, diarrhea, and death. In the USA, both ionophores and decoquinate are labeled for prevention of coccidia in goats. However, there are no drugs approved for treatment of clinical cases of coccidiosis in this species. Amprolium is labeled for treatment of coccidiosis in calves while ponazuril, a metabolite of toltrazuril, is labeled for treatment of equine protozoal myeloencephalitis. In this study, 150 young goats housed on concrete lots had fecal samples collected and McMaster fecal oocyst per gram counts performed at 0, 7, 14, and 21 days post-processing. Goats were randomly assigned to receive either amprolium (50mg/kg once a day for 5 days by mouth) or ponazuril (10mg/kg by mouth once) if they had fecal oocyst counts >5,000 per gram. Fecal samples were obtained and oocyst counts performed at days 7, 14, 21, and 28 after the cessation of treatment. Goats were weighed on days 0 and 21 post-processing. Seven goats were enrolled into the amprolium group and 8 into the ponazuril group. Both treatments resulted in decreased oocyst counts post-treatment compared to before treatment. There was no significant difference between fecal coccidian oocyst counts between goats in each group. There was no significant difference in body weight between goats in each group. This study showed that both amprolium and ponazuril were effective in decreasing fecal coccidia oocyst counts in this group of goats. Use of both drugs is currently extra-label in the USA.

    Topics: Amprolium; Animals; Body Weight; Coccidiosis; Feces; Goat Diseases; Goats; Parasite Egg Count; Random Allocation; Triazines; United States

2016
Effect of a single dose of ponazuril on neural infection and clinical disease in Sarcocystis neurona-challenged interferon-gamma knockout mice.
    Veterinary parasitology, 2003, May-30, Volume: 114, Issue:2

    Interferon gamma-knockout mice were challenged with 5000 Sarcocystis neurona sporocysts acquired from a naturally infected opossum. Ponazuril was administered once, by gavage, at day 1, 3, 7, 10, or 14 post-infection (pi). Ponazuril was given at either 20 or 200mg/kg. Mice that survived to day 30 pi were euthanized. Severity of CNS infection was quantified as schizont density in the cerebellum. Unchallenged mice in treatment and non-treatment groups remained free of disease and gained weight throughout the experiment. All challenged mice, regardless of treatment, developed histologic evidence of CNS infection even though clinical signs were prevented in some groups. The greatest treatment benefits were seen in mice given 200mg/kg ponazuril between days 4 and 14 pi. Weight gain over the course of the experiment occurred only in mice that were given 200mg/kg ponazuril on day 7 or 10 pi. With the exception of groups given 200mg/kg ponazuril on day 7 or 14 pi, mice in groups that got sporocysts developed abnormal neurologic signs. No deaths before day 30 pi occurred in mice given ponazuril at 20mg/kg on day 7 pi or 200mg/kg on day 1, 7, 10, or 14 pi. This effect was not significant. Mice given 200mg/kg on day 7 pi had significantly fewer cerebellar schizonts than did those of the control group that was not given ponazuril. These results indicate that single-dose administration of ponazuril for prevention of CNS infection is partially protective when given between days 4 and 14 pi.

    Topics: Animals; Body Weight; Cerebellum; Disease Models, Animal; Encephalomyelitis; Female; Horse Diseases; Horses; Interferon-gamma; Mice; Mice, Inbred BALB C; Mice, Knockout; Opossums; Sarcocystis; Sarcocystosis; Triazines

2003